{"id":1358,"date":"2024-01-31T14:24:28","date_gmt":"2024-01-31T14:24:28","guid":{"rendered":"https:\/\/fhucare2.laurent-angeli.fr\/event\/symposium-itox-mercredi-22-et-jeudi-23-mai-2024\/"},"modified":"2025-12-26T01:55:45","modified_gmt":"2025-12-26T00:55:45","slug":"symposium-itox-mercredi-22-et-jeudi-23-mai-2024","status":"publish","type":"post","link":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/event\/symposium-itox-mercredi-22-et-jeudi-23-mai-2024\/","title":{"rendered":"Symposium iTOX mercredi 22 et jeudi 23 mai 2024"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/fhucare2.laurent-angeli.fr\/wp-content\/uploads\/2025\/12\/itoxfull.jpeg\" alt=\"itoxfull.jpeg\" width=\"401\" height=\"131\" \/><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">Pr\u00e9parez-vous \u00e0 explorer le futur de la m\u00e9decine lors de la 7e \u00e9dition du symposium #iTOX les mercredi 22 et jeudi 23 mai 2024 !<\/a><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">Organis\u00e9 par Gustave Roussy et l&rsquo;AP-HP, Assistance Publique &#8211; H\u00f4pitaux de Paris le symposium iTOX est l&rsquo;incontournable qui explore les toxicit\u00e9s li\u00e9es aux #immunoth\u00e9rapies en #canc\u00e9rologie.<\/a><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">Deux jours de discussions anim\u00e9es par des experts pour mieux comprendre et traiter les effets ind\u00e9sirables. Soyez au rendez-vous, en personne ou en ligne !<\/a><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">Infos et inscription :&nbsp;https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr<\/a><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">Rejoignez-nous les 22 et 23 mai 2024 ! ??<\/a><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">#itox #gustaveroussy #aphp #fhu #immunotherapie #cancer<\/a><\/p>\n<p><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\">New IO treatment and new adverse events + CART cells toxicity + Organization &amp; Development + Keynote lecture +Physiopatholy<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>Comit\u00e9 scientifique&nbsp;:&nbsp;Pr. Olivier Lambotte,&nbsp;Pr. Aur\u00e9lien Marabelle,&nbsp;Dr. St\u00e9phane Champiat,&nbsp;Dr. Francois-Xavier Danlos,&nbsp;Dr. Jean-Marie Michot,&nbsp;Dr. Ariane Laparra, Dr. Florian Scotte,&nbsp;Dr. L\u00e9o Pla\u00e7ais<\/p>\n<p>Tarifs&nbsp;:&nbsp;gratuit pour les m\u00e9decins hospitaliers en formation et en exercice et CCA (mais inscription obligatoire) choisir l&rsquo;option &lsquo;tarif r\u00e9duit&rsquo; et fournir un justificatif<br \/>300\u20ac pour les salari\u00e9s de l&rsquo;industrie pharmaceutique + biotech +infirmiers lib\u00e9raux+ m\u00e9decins lib\u00e9raux (choisir l&rsquo;option plein tarif)<br \/>gratuit pour le personnel de Gustave Roussy mais inscription obligatoire (choisir l&rsquo;option GR)<\/p>\n<p>MERCREDI 22 MAI 2024<br \/>ORAL SESSION : FRENCH<br \/>Modalit\u00e9s actuelles de prescription des anticorps anti PD(L)1<br \/>9h00<br \/>Parcours patients trait\u00e9s par immunoth\u00e9rapie<br \/>Ariane Laparra<br \/>9h35<br \/>Questions en situation n\u00e9o-adjuvantes<br \/>Joana Ribeiro<br \/>10h10<br \/>Difficult\u00e9 d&rsquo;acc\u00e8s aux anti PD-1 dans les situations ayant d\u00e9montr\u00e9 leur efficacit\u00e9 mais sans AMM<br \/>Arnaud Bayle<br \/>10h45<br \/>Pause Caf\u00e9<br \/>Nouvelles immunoth\u00e9rapies: modalit\u00e9s d&rsquo;administration, d\u00e9veloppement &amp; effets ind\u00e9sirables<br \/>11h00<br \/>Traitements engageant les lymphocytes T &amp; NK<br \/>Arthur G\u00e9raud (visio)<br \/>11h35<br \/>Tebentafusp<br \/>Manuel Rodrigues &#8211; enregistrement video<br \/>12h10<br \/>CAR T cell anti CD19 dans le contexte des lymphomes c\u00e9r\u00e9braux primitifs<br \/>Marion Alcantara<br \/>12h34<br \/>Ciltacabtagene autoleucel vs teclistamab dans les myelomes<br \/>Laurent Frenzel<br \/>Pause d\u00e9jeuner<br \/>Situations d&rsquo;\u00e9checs des immunoth\u00e9rapies anti-tumorales<br \/>14h35<br \/>Hyperprogression tumorale induite par les anti PD(L)1<br \/>Roberto Ferrara<br \/>15h10<br \/>Multi-toxicit\u00e9s conduisant en r\u00e9animation: proposition de prise en charge<br \/>Na\u00efke Big\u00e9<br \/>15h45<br \/>Toxicit\u00e9s chroniques<br \/>Alexandre Maria<br \/>16h20<br \/>Pause Caf\u00e9<br \/>Pi\u00e8ges diagnostiques &#8211; Discussion de cas cliniques complexes<br \/>17h10<br \/>#1<br \/>Ariane Laparra<br \/>17h30<br \/>#2<br \/>Cl\u00e9mence H\u00e9non<br \/>17h30<br \/>#3<br \/>C\u00e9cile Cauquil<br \/>Conclusion<br \/>JEUDI 23 MAI 2024<br \/>ORAL SESSION : ENGLISH<br \/>New IO treatments and new adverse events<br \/>10h00<br \/>Tarlatamab adverse events in patients with advanced small cell lung carcinoma<br \/>St\u00e9phane Champiat<br \/>10h40<br \/>Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp<br \/>Jessica C. Hassel<br \/>11h20<br \/>Toxicity of Tumor Infiltrating Lymphocyte Therapy in advanced Melanoma<br \/>Tom Seijkens<br \/>12h00<br \/>Lunch &amp; Poster<br \/>CAR T cells toxicity<br \/>13h00<br \/>Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNg-expressing CD8 T cells<br \/>Michael Green<br \/>13h30<br \/>Overview of cytokine release syndrome related to CAR T cells therapy pathophysiology<br \/>Camille Bigenwald<br \/>Organization &amp; development<br \/>14h10<br \/>Immunotherapy Toxicity Service<br \/>Elad Sharon<br \/>14h40<br \/>To optimize B-cell depletion by CART-T cells or bispecific antibodies: From cancer to autoimmunity<br \/>Xavier Mariette<br \/>15h10<br \/>BiTox network<br \/>Sandrine Aspeslagh<br \/>15h40<br \/>Coffee break<br \/>Keynote lecture<br \/>16h00<br \/>Auto-antibodies &amp; neurologic side effects of immune checkpoint inhibitors<br \/>J\u00e9rome Honnorat<br \/>Physiopathology<br \/>17h00<br \/>Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors<br \/>Syed Shoaib Bukhari<br \/>17h30<br \/>Clonally expanded thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis<br \/>Melissa Lechner<br \/>18h00<br \/>Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors<br \/>Lukas Flatz<br \/>Conclusion<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pr\u00e9parez-vous \u00e0 explorer le futur de la m\u00e9decine lors de la 7e \u00e9dition du symposium #iTOX les mercredi 22 et jeudi 23 mai 2024 ! Organis\u00e9 par Gustave Roussy et l&rsquo;AP-HP, Assistance Publique &#8211; H\u00f4pitaux de Paris le symposium iTOX est l&rsquo;incontournable qui explore les toxicit\u00e9s li\u00e9es aux #immunoth\u00e9rapies en #canc\u00e9rologie. Deux jours de discussions [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1359,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"event_date":"mercredi 22 et jeudi 23 mai 2024 ","event_location":"Bic\u00eatre - Auditorium nouveau B\u00e2timent Recherche Facult\u00e9 de M\u00e9decine Paris Saclay ","event_time":"9h00-17h30","footnotes":""},"categories":[10],"tags":[],"class_list":["post-1358","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-event"],"_links":{"self":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/comments?post=1358"}],"version-history":[{"count":3,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1358\/revisions"}],"predecessor-version":[{"id":2545,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1358\/revisions\/2545"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/media\/1359"}],"wp:attachment":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/media?parent=1358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/categories?post=1358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/tags?post=1358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}